The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The present invention is directed at organic ammonium salts comprising

an organic ammonium-group-comprising cation which does not contain an estolide moiety and a carboxylate anion (COO—) group-comprising anion selected from the group consisting of anions containing at least one estolide moiety or carboxylate anions containing at least one internal ester group.

The invention is also directed at a process for the production of such organic ammonium salts, the use of such organic ammonium salts in cosmetic formulations for skin and hair care, the use of such organic ammonium salts for the treatment of fibers, the use of the organic ammonium salts for the treatment of hair, at compositions containing such organic ammonium salts, the use of the products of the process for the production of organic ammonium salts in cosmetic formulations for skin care and hair conditioner and hair shampoo, the use of said products for the treatment of fibers, and compositions containing said products for the treatment of hair.

A lithium battery including: a cathode; an anode; and an electrolyte between the cathode and the anode, wherein the cathode includes a cathode active material represented by Formula 1,
Li.sub.xNi.sub.yM.sub.1−yO.sub.2-zA.sub.z  Formula 1 wherein 0.95≤x≤1.2, 0.75≤y≤0.98, and 0≤z<0.2, M is Al, Mg, Mn, Co, Fe, Cr, V, Ti, Cu, B, Ca, Zn, Zr, Nb, Mo, Sr, Sb, W, Bi, or a combination thereof, and A is an element having an oxidation number of −1, −2, or −3, wherein each element of M is independently present in an amount of 0.02≤y≤0.3, wherein a total content of M is 0.02≤y≤0.3;
and wherein the electrolyte includes a lithium salt, a non-aqueous solvent, and a diallyl compound represented by Formula 2, ##STR00001## wherein L.sub.1 and L.sub.2 are each independently a single bond, a C.sub.1-C.sub.20 alkylene group, or a substituted or unsubstituted C.sub.2-C.sub.20 alkenylene group.

A lithium battery including: a cathode; an anode; and an electrolyte between the cathode and the anode, wherein the cathode includes a cathode active material represented by Formula 1,
Li.sub.xNi.sub.yM.sub.1−yO.sub.2-zA.sub.z  Formula 1 wherein 0.95≤x≤1.2, 0.75≤y≤0.98, and 0≤z<0.2, M is Al, Mg, Mn, Co, Fe, Cr, V, Ti, Cu, B, Ca, Zn, Zr, Nb, Mo, Sr, Sb, W, Bi, or a combination thereof, and A is an element having an oxidation number of −1, −2, or −3, wherein each element of M is independently present in an amount of 0.02≤y≤0.3, wherein a total content of M is 0.02≤y≤0.3;
and wherein the electrolyte includes a lithium salt, a non-aqueous solvent, and a diallyl compound represented by Formula 2, ##STR00001## wherein L.sub.1 and L.sub.2 are each independently a single bond, a C.sub.1-C.sub.20 alkylene group, or a substituted or unsubstituted C.sub.2-C.sub.20 alkenylene group.

Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.

Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.

Fatty amine compositions made from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives are disclosed. In another aspect, fatty amidoamines made by reacting a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with an aminoalkyl-substituted tertiary amine are disclosed. The fatty amines or amidoamines are advantageously sulfonated, sulfitated, oxidized, or reduced. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin.